✓ Translated by DotMD AI Clinical Council Source: Journal of the European Academy of Dermatology and Venereology : JEADV • Phase III Randomized Trial
Verify Primary Source: NIH PubMed PMID #37432045 ↗

Phase III Randomized Trial: Randomized Phase 3 trial demonstrating high efficacy, favourable safety and convenience of a novel calcipotriol and betamethasone dipropionate cream for the treatment of psoriasis (N = 490)

Original Paper Title: “Randomized Phase 3 trial demonstrating high efficacy, favourable safety and convenience of a novel calcipotriol and betamethasone dipropionate cream for the treatment of psoriasis”

Elena Rostova (AI Quant) Rigor Score
87 / 100
Sample Size (Participants)
N = 490
Evidence Classification
Phase III Randomized Trial
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • CAL/BDP PAD-cream is a novel topical treatment of psoriasis that has a high efficacy and a favourable safety profile combined with a superior patient-reported treatment convenience.
  • Study Design & Sample: Phase III Randomized Trial published in Journal of the European Academy of Dermatology and Venereology : JEADV (N = 490 human participants).
  • Biostatistical Rigor Score: 87/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in Journal of the European Academy of Dermatology and Venereology : JEADV (2023), this phase iii randomized trial evaluating 490 human participants investigated: The fixed dose combination of calcipotriene (CAL) and betamethasone dipropionate (BDP) is a well-established topical treatment option for psoriasis based on strong scientific rationale for the single agents having complementary efficacy and safety. Key clinical takeaway: CAL/BDP PAD-cream is a novel topical treatment of psoriasis that has a high efficacy and a favourable safety profile combined with a superior patient-reported treatment convenience.

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (Journal of the European Academy of Dermatology and Venereology : JEADV, 2023-11-15; N = 490; Rigor 87/100): CAL/BDP PAD-cream is a novel topical treatment of psoriasis that has a high efficacy and a favourable safety profile combined with a superior patient-reported treatment convenience.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Rx: betamethasone-dipropionate → Rx: betamethasone-valerate-foam → Rx: calcitriol → Rx: calcipotriene → Condition: guttate-psoriasis → Condition: distal-interphalangeal-psoriatic-arthropathy →
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 37432045: Phase III Randomized Trial: Randomized Phase 3 trial demonstrating high efficacy, favourable safety and convenience of a novel calcipotriol and betamethasone dipropionate cream for the treatment of psoriasis (N = 490)

3 of 3 Free Questions Remaining